An interim analysis of Covaxin’s Phase-3 trials, conducted on 25,800 volunteers across India, had indicated an overall efficacy of 78{29395a375d156e93286dd6e7185ccfdd643af63705165a979bd3711654ea3aad}. Earlier, Bharat Biotech said scientific standards and commitment of the indigenously-developed COVID-19 vaccine Covaxin are transparent, and the company has so far published nine research studies on its safety and efficacy. “Covaxin’s scientific standards+commitment is transparent. Academic journals, peer reviewers, NIV-ICMR-BB researchers -scientists,9 studys & data published,” BharatBiotech CoFounder & Joint MD Suchitra Ella said in a tweet.
The complete data for Phase I and II, and partial data for Phase III trials of Covaxin have been thoroughly scrutinised by the regulators in India, Bharat Biotech said in a statement. Covid-19 -related deaths worldwide passed a grim milestone of 4 million on Thursday, as many countries struggle to procure enough vaccines to inoculate their populations. While the number of new cases and deaths have abated in countries like the US and Britain, several nations have vaccine shortages as the Delta variant becomes the dominant strain around the world.
Maharashtra on Thursday reported 9,830 fresh COVID-19 cases and 236 fatalities and also added 400 old deaths, taking its infection tally to 59,44,710 and the toll to 1,16,026, said the state health department. Apart from the 236 new deaths, the state added 400 previously unreported fatalities to the toll as part of an ongoing reconciliation exercise, the department said. Meanwhile, Karnataka has clocked 5,983 new cases and 138 fatalities, taking the total number of infections to 27.90 lakh and the toll to 33,434.
Read all the Latest News, Breaking News and Coronavirus News here
This article includes sponsored content. The views expressed are those of the sponsor and do not necessarily reflect the official policy or position of our publication.